Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study

@inproceedings{Guo2015PrognosticAO,
  title={Prognostic analysis of Chinese patients with metastasis renal cell cancer receiving sorafenib: results from a multicenter long-term follow-up retrospective study},
  author={Fang Guo and Tao Han and Zhaozhe Liu and Xishuang Song and Qifu Zhang and Xiangbo Kong and Changfu Li and Zhenhua Li and Chengge Li and Shuxian Qu and Zhendong Zheng and Ying Piao and Yaling Han and Xiao-dong Xie},
  booktitle={OncoTargets and therapy},
  year={2015}
}
The effects of sorafenib for Chinese patients with metastatic renal cell cancer (mRCC) were evaluated to figure out the relationship between clinical variables and prognosis. The data were analyzed retrospectively from six comprehensive cancer centers in Northeast China. All cases were diagnosed as mRCC histopathologically without exception. Patients were taken 400 mg sorafenib orally twice daily until progression of disease or intolerable toxic reaction occurred. Overall survival (OS… CONTINUE READING
2 Citations
25 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…